Eli Lilly and Company (NYSE:LLY) Shares Acquired by Hart & Patterson Financial Group LLC

Hart & Patterson Financial Group LLC increased its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.0% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 679 shares of the company’s stock after buying an additional 13 shares during the period. Hart & Patterson Financial Group LLC’s holdings in Eli Lilly and Company were worth $615,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Everpar Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth approximately $1,845,000. International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 5.3% in the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock worth $7,343,000 after purchasing an additional 632 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at about $181,000. YHB Investment Advisors Inc. raised its stake in shares of Eli Lilly and Company by 7.2% in the 4th quarter. YHB Investment Advisors Inc. now owns 653 shares of the company’s stock valued at $381,000 after purchasing an additional 44 shares in the last quarter. Finally, Consolidated Portfolio Review Corp lifted its position in shares of Eli Lilly and Company by 0.5% during the fourth quarter. Consolidated Portfolio Review Corp now owns 5,720 shares of the company’s stock worth $3,334,000 after purchasing an additional 28 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up previously from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Deutsche Bank Aktiengesellschaft raised Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price target for the company from $725.00 to $1,025.00 in a research report on Monday. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Bank of America boosted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday. Finally, Barclays raised their price target on shares of Eli Lilly and Company from $913.00 to $1,025.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $945.35.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now owns 98,554,195 shares in the company, valued at $79,730,343,755. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,214,704 shares of company stock worth $1,066,841,316. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Price Performance

Shares of LLY stock traded up $23.57 during midday trading on Tuesday, reaching $907.95. 3,504,357 shares of the company were exchanged, compared to its average volume of 3,099,640. The company’s 50 day moving average price is $872.13 and its two-hundred day moving average price is $798.42. The company has a market cap of $862.92 billion, a P/E ratio of 133.72, a PEG ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 12 month low of $516.57 and a 12 month high of $966.10. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.57%. The ex-dividend date is Thursday, August 15th. Eli Lilly and Company’s payout ratio is currently 76.58%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.